Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 20/20 | 0.82 |
| ▸ | PIK3CA | P42336 | 20/20 | 0.82 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.70 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL321788 | 0.91 | PIK3CD (0.79) | PIK3CDPIK3CA | |
| SCHEMBL322391 | 0.91 | PIK3CD (0.79) | PIK3CDPIK3CA | |
| SCHEMBL403513 | 0.90 | PIK3CD (1.00) | PIK3CDPIK3CA | |
| SCHEMBL435255 | 0.90 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CB | |
| SCHEMBL438275 | 0.90 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CB | |
| SCHEMBL404284 | 0.87 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL322057 | 0.87 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL404954 | 0.87 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL322152 | 0.87 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL17289285 | 0.87 | PIK3CD (0.78) | PIK3CDPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9949979-B2 | Use of inhibitors of the activity or function of PI3K | NOVARTIS AG (CH) | 2018-04-24 | — | — | US | disclosed |
| US-20170267678-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2017-09-21 | — | — | US | disclosed |
| US-20170022199-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2017-01-26 | — | — | US | disclosed |
| US-9499536-B2 | Tetrahydro-pyrido-pyrimidine derivatives | NOVARTIS AG (CH) | 2016-11-22 | — | — | US | disclosed |
| US-20150342951-A1 | Use of Inhibitors of the Activity or Function of PI3K | NOVARTIS AG (CH) | 2015-12-03 | — | — | US | disclosed |
| US-20140128370-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2014-05-08 | — | — | US | disclosed |
| US-8653092-B2 | Tetrahydro-pyrido-pyrimidine derivatives | NOVARTIS AG (CH) | 2014-02-18 | — | — | US | disclosed |
| US-20120065183-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267678-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | PIK3CD 6/4885PIK3CA 1/4885PIK3CB 5/4885 |
| US-20120065183-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | PIK3CD 6/4885PIK3CA 1/4885PIK3CB 5/4885 |
| US-20140128370-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | PIK3CD 6/4885PIK3CA 1/4885PIK3CB 5/4885 |
| US-20170022199-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | PIK3CD 6/4885PIK3CA 1/4885PIK3CB 5/4885 |
| US-20150342951-A1 | Use of Inhibitors of the Activity or Function of PI3K | TLR9, PIK3CD, PIK3R5 | PIK3CD 2/4885PIK3CA 8/4885PIK3CB 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.